# v5.3

## Related releases

## Data changes\n
### Gene
```
CDKN2A (p14) Background Updated
CDKN2A (p14) Summary Updated
```

### Alteration
```
CDKN2A P72L Deleted
CDKN2A G65R Deleted
CDKN2A G65S Deleted
CDKN2A D68H Deleted
CDKN2A (p14) D68H Added
CDKN2A (p14) P72L Added
CDKN2A (p14) G65R Added
CDKN2A (p14) G65S Added
CDKN2A (p14) Deletion, Mutation Effect, Description Updated
CDKN2A (p14) Deletion, Mutation Effect, Effect Updated
	 New: Loss-of-function
	 Old: 
CDKN2A (p14) Deletion, Mutation Effect, Oncogenic Updated
	 New: Yes
	 Old: 
CDKN2A (p14) Deletion Added
CDKN2A (p14) Truncating Mutations, Mutation Effect, Description Updated
CDKN2A (p14) Truncating Mutations, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old: 
CDKN2A (p14) Truncating Mutations, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: 
CDKN2A (p14) Truncating Mutations Added
ERBB2 C634_S649del Name Changed
	 New: C634_S649del
	 Old: X633_splice
ERBB2 C634_S649del, Mutation Effect, Description Updated
ESR1 H356Y, Mutation Effect, Description Updated
ESR1 H356Y, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old: 
ESR1 H356Y, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old: 
ESR1 H356Y Promoted
ESR1 V418E, Mutation Effect, Description Updated
ESR1 V418E, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old: 
ESR1 V418E, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old: 
ESR1 V418E Promoted
ESR1 M421V, Mutation Effect, Description Updated
ESR1 M421V, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old: 
ESR1 M421V, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old: 
ESR1 M421V Promoted
KBTBD4 R313delinsPRR, Mutation Effect, Description Updated
KBTBD4 R313delinsPRR Name Changed
	 New: R313delinsPRR
	 Old: R297delinsPRR
KBTBD4 P311delinsPP, Mutation Effect, Description Updated
KBTBD4 P311delinsPP Name Changed
	 New: P311delinsPP
	 Old: P295delinsPP
KBTBD4 P311delinsPP, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old: Inconclusive
KBTBD4 P311delinsPP, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Inconclusive
MUTYH R274Q Name Changed
	 New: R274Q
	 Old: R260Q
MUTYH R274Q, Mutation Effect, Description Updated
MUTYH G396D, Mutation Effect, Description Updated
MUTYH G396D Name Changed
	 New: G396D
	 Old: G382D
MUTYH P405L, Mutation Effect, Description Updated
MUTYH P405L Name Changed
	 New: P405L
	 Old: P391L
MUTYH E480del Name Changed
	 New: E480del
	 Old: E466del
MUTYH E480del, Mutation Effect, Description Updated
MUTYH R109W Name Changed
	 New: R109W
	 Old: R95W
MUTYH R109W, Mutation Effect, Description Updated
MUTYH R182C Name Changed
	 New: R182C
	 Old: R168C
MUTYH R182C, Mutation Effect, Description Updated
MUTYH Y179C Name Changed
	 New: Y179C
	 Old: Y165C
MUTYH Y179C, Mutation Effect, Description Updated
MUTYH R245C Name Changed
	 New: R245C
	 Old: R231C
MUTYH R245C, Mutation Effect, Description Updated
NADK I194F, Mutation Effect, Description Updated
NADK I194F Name Changed
	 New: I194F
	 Old: I90F
PTEN R335* Deleted
RBM10 V354E Name Changed
	 New: V354E
	 Old: V419E
RBM10 V354E, Mutation Effect, Description Updated
```

### Evidence
```
CDKN2A (p14) Gene Type, Tumor Suppressor Updated
CDKN2A (p14) Deletion, AML with BCR-ABL1, Diagnostic Summary Updated
CDKN2A (p14) Deletion, AML with BCR-ABL1, Diagnostic, Description Updated
CDKN2A (p14) Deletion, AML with BCR-ABL1, Diagnostic, Level Updated
	 New: Dx2
	 Old: 
CDKN2A (p14) Deletion, AML with BCR-ABL1 Added
CDKN2A (p14) Deletion, B-Lymphoblastic Leukemia, Lymphoma, Diagnostic Summary Updated
CDKN2A (p14) Deletion, B-Lymphoblastic Leukemia, Lymphoma, Diagnostic, Description Updated
CDKN2A (p14) Deletion, B-Lymphoblastic Leukemia, Lymphoma, Diagnostic, Level Updated
	 New: Dx2
	 Old: 
CDKN2A (p14) Deletion, B-Lymphoblastic Leukemia, Lymphoma Added
CDKN2A (p14) Deletion, T-Lymphoblastic Leukemia, Lymphoma, Diagnostic Summary Updated
CDKN2A (p14) Deletion, T-Lymphoblastic Leukemia, Lymphoma, Diagnostic, Description Updated
CDKN2A (p14) Deletion, T-Lymphoblastic Leukemia, Lymphoma, Diagnostic, Level Updated
	 New: Dx2
	 Old: 
CDKN2A (p14) Deletion, T-Lymphoblastic Leukemia, Lymphoma Added
ESR1 Oncogenic Mutations {excluding Fusions}, Breast Cancer, Fulvestrant, Description Updated
ESR1 D538, E380, Y537, L536, L469V, S463P (Oncogenic ligand-binding domain missense mutations), Breast Cancer, Elacestrant, Description Updated
ESR1 V422del (Oncogenic ligand-binding domain in-frame insertions or deletions), Breast Cancer, Elacestrant, Description Updated
H3-3A K28M, Diffuse Midline Glioma, H3 K27-Altered, Summary Updated
H3-3A K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, Description Updated
H3-3A K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, FDA Level Updated
	 New: Fda2
	 Old: no
H3-3A K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, Level Updated
	 New: 1
	 Old: 
H3-3A K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, Propagation to Other Liquid Tumor Types Updated
H3-3A K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, Propagation to Other Solid Tumor Types Updated
H3-3A K28M, Diffuse Midline Glioma, H3 K27-Altered Added
H3-3A K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone 1 Added
H3-3A K28M, Other Tumor Types, Summary Updated
H3-3A K28M, Other Tumor Types Added
H3C2 K28M, Diffuse Midline Glioma, H3 K27-Altered, Summary Updated
H3C2 K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, Description Updated
H3C2 K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, FDA Level Updated
	 New: Fda2
	 Old: no
H3C2 K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, Level Updated
	 New: 1
	 Old: 
H3C2 K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, Propagation to Other Liquid Tumor Types Updated
H3C2 K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, Propagation to Other Solid Tumor Types Updated
H3C2 K28M, Diffuse Midline Glioma, H3 K27-Altered Added
H3C2 K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone 1 Added
H3C2 K28M, Other Tumor Types, Summary Updated
H3C2 K28M, Other Tumor Types Added
H3C3 K28M, Diffuse Midline Glioma, H3 K27-Altered, Summary Updated
H3C3 K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, Description Updated
H3C3 K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, FDA Level Updated
	 New: Fda2
	 Old: no
H3C3 K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, Level Updated
	 New: 1
	 Old: 
H3C3 K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, Propagation to Other Liquid Tumor Types Updated
H3C3 K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone, Propagation to Other Solid Tumor Types Updated
H3C3 K28M, Diffuse Midline Glioma, H3 K27-Altered Added
H3C3 K28M, Diffuse Midline Glioma, H3 K27-Altered, Dordaviprone 1 Added
H3C3 K28M, Other Tumor Types, Summary Updated
H3C3 K28M, Other Tumor Types Added
```